LONDON, May 16 (Reuters) - Hikma Pharmaceuticals PLC
* Hikma pharmaceutical - interim management statement
* Branded and injectables businesses are on track to meet our current FY
guidance for 2013
* Now expect group revenue to grow by around 13% in 2013, up from our previous
guidance of around 10%
* On a constant currency basis, we continue to expect branded revenue growth to
be around 11% in 2013
Source Text for Eikon




















